Likarda, a Kansas City, Kansas-based biotech research laboratory focused on advancing diabetes treatments for dogs and cat, raised $4m in Series A funding.
Werth Family Investment Associates made the investment.
Founded in 2012 by Lisa Stehno-Bittel, Ph.D., President & Co-Founder, Likarda is a regenerative medicine company advancing a proprietary diabetes treatment for dogs and cats. Their insulin-producing cell clusters, called the Kanslet™, can be infused into animals with diabetes. Through years of development and working with various partners, Likarda is in the process of bringing islet transplants to dogs. The microencapsulated islets (the insulin-producing cells of the body) are transplanted via injection into the belly of a diabetic dog, removing the need for twice daily insulin injections.
The company intends to use the funds to scale the project from hundreds of animals to thousands in the treatment of diabetic pets. The clinical research program is being finalized and is expected to launch by the end of 2017.